Skip to main content
GRCE logo

GRCE · Grace Therapeutics, Inc.

$2.43 +0.00 (+0.00%) At close · Jul 21
Market Cap
$38.81M
Shares
16.27M

Total shares sold short and not yet covered, reported to FINRA by broker-dealers and published twice a month (bi-monthly). Days to cover divides the short position by average daily volume; a high value (above 5) can signal short-squeeze potential.

Short Squeeze Score
63/100
Short interest 10.5% of shares — P90 Days to cover 5.1 — P81 Price vs VWAP -5.7% — P36 Short-volume trend -6.8% — P27 Short interest change -10.4% — P25 Worst FTD 0.10% of shares — P76

Peer-relative percentile rank across all stocks reporting short interest at the latest settlement date (2026-06-30). Weighted mean of the available factors (short interest 30%, days to cover 20%, price vs VWAP 15%, short-volume trend 15%, short-interest change 10%, fails-to-deliver 10%) plus catalyst boosts (price spike, volume surge, earnings within days), capped at +20 and clamped to 100.

Short Interest History

Settlement Date Current Position Previous Position Change Days to Cover
2026-06-30 1,705,143 1,902,823 -197,680 5.06
2026-06-15 1,902,823 2,015,007 -112,184 6.95
2026-05-29 2,015,007 2,098,572 -83,565 6.71
2026-05-15 2,098,572 2,199,232 -100,660 4.40
2026-04-30 2,199,232 1,948,693 +250,539 1.42
2026-04-15 1,948,693 1,652,768 +295,925 1.53
2026-03-31 1,652,768 1,565,407 +87,361 3.27
2026-03-13 1,565,407 390,568 +1,174,839 3.33
2026-02-27 390,568 65,459 +325,109 2.16
2026-02-13 65,459 38,490 +26,969 1.20
2026-01-30 38,490 42,809 -4,319 1.00
2026-01-15 42,809 31,816 +10,993 1.00
2025-12-31 31,816 24,289 +7,527 1.00
2025-12-15 24,289 17,729 +6,560 1.00
2025-11-28 17,729 26,759 -9,030 1.00
2025-11-14 26,759 22,196 +4,563 1.00
2025-10-31 22,196 23,235 -1,039 1.00
2025-10-15 23,235 352,260 -329,025 1.00
2025-09-30 352,260 209,523 +142,737 5.36
2025-09-15 209,523 130,836 +78,687 2.21
2025-08-29 130,836 80,165 +50,671 1.34
2025-08-15 80,165 76,314 +3,851 1.00
2025-07-31 76,314 65,340 +10,974 1.24
Showing 1–23 of 23 settlements
Key facts CIK 1444192 CUSIP 00439U104 13F (30d) 2 filings 2 filers Visit website Investor relations